Former Director General of the ABPI, Prof Jones has occupied a number of roles as a member of several distinguished agencies, including the Medicines Commission, an adviser to the Cabinet Office on the Human Genome project 2001, the Prime Minister’s Task Force on the Competitiveness of the Pharmaceutical Industry (PICTF) and Chair of the Government Advisory Group on Genetics Research. From 2003-2005 he was a Commissioner at the World Health Organisation (WHO) on the Commission for Intellectual Property, Innovation and Public Health (CIPIH).
Steve Moore is Founder and Strategic Counsel for the MCA and the Association for the Cannabinoid Industry (ACI) with 25 years experience of working in social change and political campaigns. He directed the campaign with Charlotte Caldwell to reform policy relating to the access of medicinal cannabis. He co-founded the Centre for Medicinal Cannabis. Steve was formerly Chief Executive of David Cameron’s Big Society Network and has curated change programmes for Channel 4 Television, the Royal Society of Arts and PWC.
A clinical neuroscientist and integrative medicine practitioner who founded a consultancy specialising in brain health, the endocannabinoid system and phytocannabinoids including CBD and medicinal cannabis. Dr Philipps’ focus includes translational research and clinical and industry education around the body’s endocannabinoid system and cannabinoid product, with particular emphasis on the use of cannabinoid medicine for traumatic brain injuries in professional sports.
Dr Bhatarah has over 20 years’ experience within the international pharmaceutical industry & regulatory environment. She has 12 years’ experience in the Medicinal Cannabis industry, covering everything from cultivation to FDA approval of finished medicinal products, and has expertise in product development for clinical trials, commercial launch, technology transfer and manufacturing.
Dr Yates has over 25 years’ experience in pharma and biotech, working in R&D, medical affairs, commercial, business development and strategy functions. He serves as Chief Scientific Officer at Artelo Biosciences and has extensive experience in all aspects of medicine development programmes including three cannabinoid-based medicines within Artelo’s portfolio. Andy is a UK pharmacist who received his PhD in cannabinoid medicinal chemistry from the University of Nottingham.
Jimmy has worked as a journalist for a decade, lately specialising in the impact of CBD regulation on food and drink. He has previously written about corporate governance, financial regulation and local government.
Bill has working in corporate communications for over 25 years across multiple sectors including healthcare, banking, travel and telecommunications..
Political Strategy Associate